

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1.-14. (canceled).

15. (currently amended): The A method for treating multiple myeloma by both inhibiting proliferation of myeloma cells and suppressing bone resorption comprising, administering to a patient suffering from multiple myeloma and bone lesions according to claim 14, wherein the pharmaceutically effective amount 1 to 20 mg per day of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid, or a salt thereof is 1 to 20 mg per day, and a pharmaceutically acceptable carrier or diluent.

16. (currently amended): The A method for treating multiple myeloma by both inhibiting proliferation of myeloma cells and suppressing bone resorption comprising according to claim 14, administering to a patient suffering from multiple myeloma and bone lesions wherein the pharmaceutically effective amount 3 to 10 mg per day of 1-hydroxy-2-(imidazo[1,2-a]pyridin-3-yl)ethane-1,1-bisphosphonic acid, or a salt thereof is 3 to 10 mg per day, and a pharmaceutically acceptable carrier or diluent.

17. (currently amended): The A method for treating multiple myeloma by both inhibiting proliferation of myeloma cells and suppressing bone resorption comprising according to any one of claims 14-16, orally administering to a patient suffering from multiple myeloma and bone lesions wherein the a pharmaceutically effective amount of 1-hydroxy-2-(imidazo[1,2-

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. §1.116  
U.S. Appl. No. 09/869,122

Q64929

a]pyridin-3-yl)ethane-1,1-bisphosphonic acid, or a salt thereof ~~is administered orally, and a~~  
pharmaceutically acceptable carrier or diluent.

18.-21. (canceled).